Correspondence | Published:

Outcomes of a novel rituximab-based non-myeloablative conditioning regimen for hematopoietic cell transplantation in severe aplastic anemia

Bone Marrow Transplantationvolume 53pages795799 (2018) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Bacigalupo A, Brand R, Oneto R, Bruno B, Socié G, Passweg J, et al. Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy—The European Group for Blood and Marrow Transplantation experience. Semin Hematol. 2000;37:69–80.

  2. 2.

    Bacigalupo A, Locatelli F, Lanino E, Marsh J, Socié G, Maury S, et al. Fludarabine, cyclophosphamide and anti-thymocyte globulin for alternative donor transplants in acquired severe aplastic anemia: a report from the EBMT-SAA Working Party. Bone Marrow Transplant. 2005;36:947–50.

  3. 3.

    Bacigalupo A. Bone marrow transplantation for severe aplastic anemia. Hematol Oncol Clin N Am. 2014;28:1145–55.

  4. 4.

    Bacigalupo A, Sica S. Alternative donor transplants for severe aplastic anemia: current experience. Semin Hematol. 2016;53:115–19.

  5. 5.

    Holtan SG, DeFor TE, Lazaryan A, Bejanyan N, Arora M, Brunstein CG, et al. Composite end point of graft-versus-host disease, relapse-free survival after allogeneic stem cell transplantation. Blood. 2015;125:1333–38.

  6. 6.

    Gupta V, Eapen M, Brazauskas R, Carreras J, Aljurf M, Gale RP, et al. Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica. 2010;95:2119–25.

  7. 7.

    Dominietto A, Tedone E, Soracco M, Bruno B, Raiola AM, Van Lint MT, et al. In vivo B-cell depletion with rituximab for alternative donor hematopoietic SCT. Bone Marrow Transplant. 2012;47:101–6.

  8. 8.

    Coppoletta S, Tedone E, Galano B, Soracco M, Raiola AM, Lamparelli T, et al. Rituximab treatment for Epstein-Barr virus DNAemia after alternative-donor hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2011;17:901–7.

  9. 9.

    Liu W, Wu D, Hu T, Ye B. Efficiency of treatment with rituximab in platelet transfusion refractoriness: a study of 7 cases. Int J Clin Exp Med. 2015;8:14080–4.

  10. 10.

    Liu W, Hu Z, Lin S, He J, Zhou Y. Systemic lupus erythematosis with severe aplastic anemia successfully treated with rituximab and antithymocyte globulin. Pak J Med Sci. 2014;30:449–51.

  11. 11.

    Gomez-Almaguer D, Jaime-Perez JC, Ruiz-Arguelles GJ. Antibodies in the treatment of aplastic anemia. Arch Immunol Ther Exp (Warsz). 2012;60:99–106.

  12. 12.

    Takamatsu H, Yagasaki H, Takahashi Y, Hama A, Saikawa Y, Yachie A, et al. Aplastic anemia successfully treated with rituximab: the possible role of aplastic anemia-associated autoantibodies as a marker for response. Eur J Haematol. 2011;86:541–5.

  13. 13.

    Dufour C, Svahn J, Bacigalupo A, on Behalf of the Severe Aplastic Anemia Working Party of the EBMT. Front-line immunosuppressive treatment of acquired aplastic anemia. Bone Marrow Transplant. 2013;48:174–77.

  14. 14.

    Bacigalupo A, Socié G, Lanino E, Prete A, Locatelli F, Locasciulli A, et al. Fludarabine, cyclophosphamide, antithymocyte globulin, with or without low dose total body irradiation, for alternative donor transplants, in acquired severe aplastic anemia: a retrospective study from the EBMT-SAA working party. Hematologica . 2010;95:976–82.

  15. 15.

    Clay J, Kulasekararaj AG, Potter V, Grimaldi F, McLornan D, Raj K, et al. Nonmyeloablative peripheral blood haploidentical stem cell transplantation for refractory severe aplastic anemia. Biol Blood Marrow Transplant. 2014;20:1711–6.

Download references

Acknowledgements

The authors would like to acknowledge the contribution of Justin D. Gatwood, PhD, MPH to this manuscript.

Author information

Affiliations

  1. Department of Pharmacy, Vanderbilt University Medical Center, Nashville, TN, USA

    • Katie S. Gatwood
    •  & Kathryn A. Culos
  2. Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    • Laura A. Binari
  3. Division of Hematology/Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA

    • Brian G. Engelhardt
    • , Adetola Kassim
    • , Michael T. Byrne
    • , Stacey A. Goodman
    • , Wichai Chinratanalab
    • , Salyka M. Sengsayadeth
    • , John P. Greer
    • , Madan Jagasia
    •  & Bipin N. Savani

Authors

  1. Search for Katie S. Gatwood in:

  2. Search for Kathryn A. Culos in:

  3. Search for Laura A. Binari in:

  4. Search for Brian G. Engelhardt in:

  5. Search for Adetola Kassim in:

  6. Search for Michael T. Byrne in:

  7. Search for Stacey A. Goodman in:

  8. Search for Wichai Chinratanalab in:

  9. Search for Salyka M. Sengsayadeth in:

  10. Search for John P. Greer in:

  11. Search for Madan Jagasia in:

  12. Search for Bipin N. Savani in:

Conflict of interest

KSG and BNS serve on a Speakers Bureau for Jazz Pharmaceuticals. The remaining authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Katie S. Gatwood.

About this article

Publication history

Received

Revised

Accepted

Published

Issue Date

DOI

https://doi.org/10.1038/s41409-018-0124-6